NEWS：New website of Shanghai Jenomed officially launched

With the rapid growth of the company and continuing increase of the company's products and services, Shanghai Jenomed Biotech Co., Ltd. recently upgraded and improved its official website from the aspects of R&D services, product display and user experience. The new website (http://www.jenomed.com) was officially launched on January 18, 2019.

CTC and ctDNA early detection service was added to the new website. The pain point of cancer treatment lies in the early detection and diagnosis of cancer. At present, the 5-year survival rate of cancer patients in China is 35-40%, compared with approximately 70% in the US and other developed countries. The discrepancies are mainly due to that a considerable number of cancer patients in China are in advanced stages when they first go to hospital to seek diagnosis and the tumor has metastasized, which makes treatment less likely to succeed and reduces their chances of survival. Therefore, CTC detection is of great importance in early screening and diagnosis of tumors. In addition, the difficulty of cancer treatment lies in its metastasis, and CTCs have a potentially high capacity of metastasis. We adopted an advanced microfluid chip technology that allows separation of CTCs from the background leukocytes and improve sample purity up to 10-40% in less than 10 cells collected over other methods that capture cells in aggregates. It recovers single or several CTCs from the microfluidic chip for PCR, NGS and other analyses, such as SNP, TMB, MSI and CIN, for the early diagnosis and companion diagnosis of cancer.

Personalized cancer vaccine (PCV) R&D service was also added to the new website. The company has established mouse models of lung cancer and melanoma and carried out some preclinical studies. CTC and ctDNA have been noninvasively isolated and enriched in the plasma of early lung cancer animals and cancer patients. Neoantigens have been identified by combining WES and RNA-seq of CTC and PBMCs. PCVs, based on selected neoantigens, were prepared to promptly stimulate the immune response of cancer patients and animal tumor models.

Our proprietary and leading-edge animal mammary gland bioreactor platform is a natural and unique system for expression of difficult to express proteins including membrane proteins, VLP, mABs and other complex proteins. Specifically, it suits expression of membrane proteins well including ion channels, GPCR and transport proteins, and the membrane protein may not be secreted as a soluble protein, but as a part of naturally existed milk fat globule membrane (MFGM) with a typical lipid bilayer and an additional monolayer. We guaranteed high-level expression of vast majority of target proteins (>1mg/ml) in the milk. Proteins can be purified of 90% purity.

Some new products are also beginning to be sold to the market: newly upgraded effervescent pesticide cleaning tablets for fruit and vegetables, using single independent moisture-proof packaging, are more convenient to use and preserve. Meanwhile, we also sell some bio-medical products, medical devices, reagents and consumables.

In addition, the new version of the page layout is clearer, more beautiful, and more convenient for business inquiries. Hoping through this upgrade and improvement, we can better publicize the company's services and products, better improve user experience, and better serve our customers.